Recombinant grass pollen vaccine - Biomay

Drug Profile

Recombinant grass pollen vaccine - Biomay

Alternative Names: BM-32; CS-BM32-001

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomay
  • Class Allergens; Antiallergics; Plant allergy immunotherapies; Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Allergic rhinitis; Hypersensitivity

Most Recent Events

  • 26 Jan 2017 Adverse events and efficacy data from a phase IIb trial in Hypersensitivity released by Biomay AG
  • 01 Jan 2017 Biomay completes a phase II trial in Hypersensitivity in Austria (SC) (NCT02643641)
  • 10 Nov 2016 Recombinant grass pollen vaccine - Biomay AG is available for licensing as of 10 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top